NCT00130286

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the treatment of fat accumulation in people with HIV infection and insulin resistance.

Detailed description

A number of people with HIV infection who gain weight in the abdomen (sometimes called lipodystrophy) also have a high level of the sugar-controlling hormone called insulin. These people need to produce this extra insulin to help keep their blood sugar normal. This is called "insulin resistance." Studies have shown that growth hormone (also called "Serostim") can decrease abdominal fat, but it can also worsen the insulin resistance. Rosiglitazone (also called "Avandia") is used to treat insulin resistance in people who have diabetes, so we want to see if taking growth hormone and rosiglitazone together will be better for treating the fat accumulation part of lipodystrophy than either drug alone or no active therapy. The study is 24 weeks long, divided into two 12-week parts. The first part of the study is double-blind, meaning that neither participants nor the study staff will know which drugs participants are on. Participants will be assigned randomly (like flipping a coin) to one of four groups: 1. Growth hormone (one injection, daily) PLUS rosiglitazone (one tablet, twice daily). 2. Growth hormone PLUS rosiglitazone placebo ("sugar pill"). 3. Growth hormone placebo (plain water injection) PLUS rosiglitazone. 4. Growth hormone placebo PLUS rosiglitazone placebo. Everyone in the study will need to be hospitalized overnight for special tests at the beginning of the study and at week 12. The second part of the study is open-label, meaning that participants and the study staff will know which drugs participants are receiving. All volunteers will receive both active drugs: * Growth hormone (one 2 mg injection, every other day) PLUS rosiglitazone (one 4 mg tablet, twice daily).

Conditions

• HIV-Associated Lipodystrophy Syndrome
• Insulin Resistance
• HIV Infections
• Metabolic Syndrome X
• Body Weight Changes

Interventions

Type	Name	Description
DRUG	Rosiglitazone	4 mg tablet twice a day x 12 weeks (double-blind phase)
DRUG	Recombinant human growth hormone + rosiglitazone	Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Timeline

• Start date: 2005-03-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2005-08-15
• Last updated: 2014-02-13
• Results posted: 2014-02-13

Locations

4 sites across 1 country: United States